EGFR and medical procedure: Considering the limitations and the cost of ctDNA NGS approaches, we monitored free circMET in the plasma of an EGFR-mutated advanced lung ADK patient (case #5 in Table S2) under treatment with a first-generation tyrosine kinase inhibitor (Fig. 6a).